We are live on ! Find out more
RVMD icon

Revolution Medicines

184 hedge funds and large institutions have $4.64B invested in Revolution Medicines in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 81 increasing their positions, 34 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 34

87% more call options, than puts

Call options by funds: $19.1M | Put options by funds: $10.2M

50% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 36

49% more capital invested

Capital invested by funds: $3.11B → $4.64B (+$1.52B)

44% more funds holding in top 10

Funds holding in top 10: 913 (+4)

10% more funds holding

Funds holding: 168184 (+16)

4.28% less ownership

Funds ownership: 102.97%98.68% (-4.3%)

Holders
184
Holders Change
+16
Holders Change %
+9.52%
% of All Funds
2.68%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.19%
New
54
Increased
81
Reduced
34
Closed
36
Calls
$19.1M
Puts
$10.2M
Net Calls
+$8.88M
Net Calls Change
+$5.64M
Name Holding Trade Value Shares
Change
Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$46.5M +$9.88M +411,165 +34%
Northern Trust
27
Northern Trust
Illinois
$36.4M +$8.11M +337,670 +36%
Marshall Wace
28
Marshall Wace
United Kingdom
$34.7M +$27M +1,122,841 +1,304%
BCLSI
29
Bain Capital Life Sciences Investors
Massachusetts
$31.9M +$26.7M +1,112,396 New
Goldman Sachs
30
Goldman Sachs
New York
$30.2M +$10.2M +425,812 +68%
Charles Schwab
31
Charles Schwab
California
$29.9M +$6.64M +276,298 +36%
FLSM
32
Frazier Life Sciences Management
California
$28.6M
Citadel Advisors
33
Citadel Advisors
Florida
$25.9M +$15.8M +657,571 +267%
PA
34
Perceptive Advisors
New York
$23.5M -$12.1M -502,913 -38%
RSCM
35
Rock Springs Capital Management
Maryland
$20.8M
VPC
36
Vestal Point Capital
New York
$20.8M +$17.4M +725,000 New
TCM
37
Tang Capital Management
California
$19.5M +$16.3M +679,630 New
FC
38
Finepoint Capital
Massachusetts
$17.7M +$4.57M +190,100 +45%
CS
39
Candriam SCA
Luxembourg
$17.4M +$1.08M +45,002 +8%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$16.7M +$3.87M +160,850 +38%
Balyasny Asset Management
41
Balyasny Asset Management
Illinois
$16.3M -$9.5M -395,552 -41%
Victory Capital Management
42
Victory Capital Management
Texas
$16M +$5.19M +216,010 +63%
DCM
43
DAFNA Capital Management
California
$14.7M +$925K +38,500 +8%
MCMU
44
MIC Capital Management (UK)
United Kingdom
$14.6M +$12.2M +508,569 New
N
45
Nuveen
North Carolina
$11M +$2.64M +109,723 +40%
Rafferty Asset Management
46
Rafferty Asset Management
New York
$10.5M +$3.32M +138,153 +61%
EAM
47
Eventide Asset Management
Massachusetts
$10.4M
Barclays
48
Barclays
United Kingdom
$10.1M +$3.01M +125,124 +55%
LGM
49
Logos Global Management
California
$10M +$2.4M +100,000 +40%
AllianceBernstein
50
AllianceBernstein
Tennessee
$9.18M +$1.54M +64,202 +25%

RVMD Hedge Fund Activity: Q4 2023 in Review

184 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2023, worth a combined $4.64B — up 49% from $3.11B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new RVMD positions and 36 closed out — a net gain of 18 holders — while 81 added to existing stakes and 34 trimmed.

The largest buyer was Alphabet Inc, opening a new position worth an estimated $127M. The largest seller was EcoR1 Capital, cutting an estimated $131M.

  • 184 institutional investors held Revolution Medicines (RVMD) as of Q4 2023, up from 168 in Q3 2023.
  • Funds reported $4.64B of Revolution Medicines stock for Q4 2023, up 49% quarter-over-quarter.
  • 54 funds opened new Revolution Medicines positions in Q4 2023 and 36 closed out, a net change of +18 holders.
  • The largest Revolution Medicines buyer in Q4 2023 was Alphabet Inc, an estimated $127M added.
  • The largest Revolution Medicines seller in Q4 2023 was EcoR1 Capital, an estimated $131M sold.

Based on aggregated 13F filings for Q4 2023.